Literature DB >> 28357075

De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton-related protein coding regions.

Rebecca J Stoll1, Grace R Thompson1, Mohammad D Samy1, George Blanck2.   

Abstract

Human mutagenesis is largely random, thus large coding regions, simply on the basis of probability, represent relatively large mutagenesis targets. Thus, we considered the possibility that large cytoskeletal-protein related coding regions (CPCRs), including extra-cellular matrix (ECM) coding regions, would have systemic nucleotide variants that are not present in common SNP databases. Presumably, such variants arose recently in development or in recent, preceding generations. Using matched breast cancer and blood-derived normal datasets from the cancer genome atlas, CPCR single nucleotide variants (SNVs) not present in the All SNPs(142) or 1000 Genomes databases were identified. Using the Protein Variation Effect Analyzer internet-based tool, it was discovered that apparent, systemic mutations (not shared among others in the analysis group) in the CPCRs, represented numerous deleterious amino acid substitutions. However, no such deleterious variants were identified among the (cancer blood-matched) variants shared by other members of the analysis group. These data indicate that private SNVs, which potentially have a medical consequence, occur de novo with significant frequency in the larger, human coding regions that collectively impact the cytoskeleton and ECM.

Entities:  

Keywords:  The Cancer Genome Atlas; breast cancer; cytoskeleton-related protein coding regions; genetic testing; private variants; single nucleotide variants; systemic mutations

Year:  2016        PMID: 28357075      PMCID: PMC5351269          DOI: 10.3892/br.2016.826

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  8 in total

1.  Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA.

Authors:  E Ballestar; T M Yusufzai; A P Wolffe
Journal:  Biochemistry       Date:  2000-06-20       Impact factor: 3.162

Review 2.  Muscle giants: molecular scaffolds in sarcomerogenesis.

Authors:  Aikaterini Kontrogianni-Konstantopoulos; Maegen A Ackermann; Amber L Bowman; Solomon V Yap; Robert J Bloch
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

3.  Unifying the genomics-based classes of cancer fusion gene partners: large cancer fusion genes are evolutionarily conserved.

Authors:  Libia M Pava; Daniel T Morton; Ren Chen; George Blanck
Journal:  Cancer Genomics Proteomics       Date:  2012-11       Impact factor: 4.069

4.  Big genes are big mutagen targets: a connection to cancerous, spherical cells?

Authors:  Michele L Parry; Michael Ramsamooj; George Blanck
Journal:  Cancer Lett       Date:  2014-10-16       Impact factor: 8.679

Review 5.  Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies.

Authors:  Shea A Ford; George Blanck
Journal:  Biochim Biophys Acta       Date:  2014-11-07

6.  Genes that contribute to cancer fusion genes are large and evolutionarily conserved.

Authors:  Swetha Narsing; Zhihong Jelsovsky; Alfred Mbah; George Blanck
Journal:  Cancer Genet Cytogenet       Date:  2009-06

7.  Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?

Authors:  Michele L Parry; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2015-07-30       Impact factor: 3.452

8.  A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates.

Authors:  Timothy J Fawcett; Michele L Parry; George Blanck
Journal:  Cancer Genomics Proteomics       Date:  2015 Nov-Dec       Impact factor: 4.069

  8 in total
  1 in total

1.  MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development.

Authors:  John M Yavorski; George Blanck
Journal:  Mol Clin Oncol       Date:  2017-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.